PVSs were performed 6 days (5-7) after ablation (186 noninvasive programmed stimulations and 32 invasive PVS) in 210 consecutive patients (ischemic, 48%; median left ventricular ejection fraction, 37%; syncope, 35% with trauma associated 6%), while patients were awake and under β-blocker therapy. After ablation, implantable cardioverter defibrillators were programmed according to noninvasive programmed stimulations results (class A-noninducible; class B-nondocumented inducible VT; and class C-documented inducible VT), with high and delayed VT detection intervals. Concordance between PVS end procedure and PVS day 6 was 67%. Positive predictive value and negative predictive value were higher for PVS day 6 (53% and 88% versus 43% and 71%). Ischemic and patients with preserved ejection fraction showed the highest negative predictive value (91% and 96%). Among 46 of 174 (26%) noninducible patients at PVS end procedure, but inducible at day 6, 59% had VT recurrence at 1-year follow-up; recurrences were 9% when both studies were noninducible. There were no inappropriate shocks; incidence of syncope was 3%; and none was harmful. The rate of appropriate shocks per patient per month according to noninvasive programmed stimulations results was significantly reduced, comparing the month before and after ablation ( CONCLUSIONS: PVS at day 6 predicts VT recurrence more accurately allowing to identify patients who might benefit from a redo ablation and addressing implantable cardioverter defibrillator programming.
C
atheter ablation of ventricular tachycardia (VT) is effective at reducing appropriate implantable cardioverter defibrillator (ICD) shocks. Prevention of VT induction by programmed ventricular stimulation (PVS) after ablation is the goal of ablation success assessment. Recently, single-and multicenter studies have proven a strong link between noninducibility in postinfarction VT and lower recurrence and mortality rates. [1] [2] [3] [4] In spite of these favorable features, the arrhythmia recurrence rate in noninducible patients is still substantial, ranging from 20% to 30% at 1-year followup (FU) even in the most favorable series. 5, 6 Multiple reasons may account for this discrepancy, including the probabilistic nature of the test, the residual effect of general anesthesia, different settings of autonomic tone, and the reversibility of the thermal lesion after ablation. To partially eliminate these confounders, Frankel et al 7 have reported on the possibility of repeating VT inducibility test, 3 days after ablation through the ICD lead.
In patients with an ICD for primary prevention, the risk of death is significantly increased by both appropriate and inappropriate shock therapies, with a stronger association for appropriate. 8 Previous trials on the ICD therapy reduction programming have shown a significant decrease of inappropriate shocks and mortality in primary prevention and reduction of inappropriate therapies and appropriate shocks in the secondary prevention population. 9, 10 In the present study, we aimed to describe our extended experience on the systematic use of noninvasive programmed stimulation (NIPS) to assess procedural outcome and to direct further strategies including ICD programming.
METHODS
Consecutive patients with structural heart disease undergoing VT ablation at the San Raffaele University Hospital, Milan, from May 2013 to September 2015, were included in the study. The study was approved by an institutional review committee. Written informed consent was obtained in all subjects. The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
PVS at Ablation Procedure
Procedures were performed under general anesthesia. PVS was performed with stimuli 2 ms in duration at twice diastolic threshold up to 4 extrastimuli at 2 basic drive cycle length (500 and 400 ms), at the right ventricular apex and
WHAT IS KNOWN?
• Ventricular tachycardia recurrence rate is still substantial in noninducible patients after ventricular tachycardia ablation.
• Delayed and high rate settings for defibrillator therapies have shown a reduction in the number of shocks and improved survival in primary prevention population.
WHAT THE STUDY ADDS?
• A relatively high percentage of patients being noninducible at the end of the ablation session have inducible ventricular tachycardia just a few days after the procedure 46 of 174 (26%). This divergence has prognostic significance with higher ventricular tachycardia recurrence rate (59%) in those inducible patients at first-year follow-up. • Recurrence rate is 9% when reaching noninducibility in both studies. Negative predictive value of the late programmed ventricular stimulation is 88%; the implantable cardioverter defibrillator programming strategy of high and delayed therapy may benefit this particular population.
at multiple left ventricular sites. Coupling intervals of extrastimuli were decreased in 10-ms intervals until refractoriness or induced VT. Prevention of inducibility of any VT was defined as complete success (class A), persistent inducibility of any nondocumented sustained VT as partial success (class B), and the induction of some previously documented VTs as a failure (class C). 1 All induced sustained monomorphic VTs during the ablation procedure were categorized and compared with the clinical VT records when available and those induced at late PVS.
Noninvasive Programmed Stimulation
The study was performed within 5 to 7 days after ablation, before hospital discharge in clinically stable patients under β-blocker therapy, in the awake state, from the right ventricular ICD lead (up to 3 extrastimuli on drive trains of 500 and 400 ms). Coupling intervals of extrastimuli were decreased in 10-ms intervals until refractoriness or induced VT. The output was 5 V×0.4 ms as is the setting determined by the ICD programmers for the NIPS. In patients without ICD, PVS was performed invasively by a quadripolar catheter advanced to the right ventricular apex, stimulation with 2 ms in duration at 2× diastolic threshold up and same protocol.
The ICD programming parameters according to inducibility at NIPS and trying to overcome manufacturer's differences are included in the Data Supplement.
Follow-Up
The arrhythmia episodes were recorded through home monitoring or at outpatient FU visits. Referring cardiologists were contacted for patients not followed up at our institution, and ICD reports were analyzed.
Arrhythmia presentation was classified as electrical storm, incessant, or paroxysmal VT as previously described. 1 Patients who were treated by both ATP and shock were considered as treated by shock for the analysis of modalities of ICD treatment of recurrences. Patients without ICD before ablation and 1 patient with a subcutaneous ICD were excluded from the analysis of modalities of ICD treatment of recurrences (n=33).
Statistical Analysis
Continuous variables are presented as means (±SD) or medians (25th and 75th percentiles) and categorical variables as numbers and percentages. Comparisons between groups were undertaken using the t test or nonparametric tests (Wilcoxon rank test) for continuous variables and Fisher exact or χ 2 tests for proportions as indicated. For comparisons between events before and after the procedure, Wilcoxon test was used for continuous nonparametric variables and McNemar test for categorical variables. Event-free survival was estimated by the Kaplan-Meier method; we compared those patients inducible to those noninducible at the end of the procedure and same comparison 6 days later, using the log-rank test. This analysis was repeated in the subgroup of patients with ischemic cardiomyopathy, nonischemic cardiomyopathy, left ventricular ejection fraction (LVEF) >35%, and LVEF <35% for PVS end procedure and PVS day 6. The proportion of the positive tests results which are actually positive is the positive predictive value (PPV). The proportion of negative test results which are actually negative is the negative predictive value (NPV). Differences were considered statistically significant at the 2-sided P<0.05 level. All analyses were undertaken using IBM SPSS Statistics Version 21 (IBM Corporation).
RESULTS
A total of 342 procedures were performed in 286 patients during the study period. The PVS at the end of the procedure was performed in 307, 9 were lost to FU resulting in a final count of 298 PVS studies to include in the analysis.
Two hundred twenty-six postprocedural electrophysiological studies were performed in 210 patients (2 procedures in 14 patients and 3 in 1) in a median time from RF catheter ablation of 6 days (5-7). Out of 226 studies, 8 were excluded leading to a final number of 218 late PVS included in the analysis ( Figure 1 ).
Study Population
Ischemic heart disease accounts for 48% of patients, arrhythmogenic right ventricular cardiomyopathy 11%, and nonischemic cardiomyopathy 41%. Syncope occurred in 76 patients (35%) before ablation, and in 14 (6%) of them, it was associated with trauma; 23 patients (11%) had experienced cardiac arrest and 20 patients (9%) inappropriate shocks.
Patients in whom PVS at day 6 was not performed (n=76) were more frequently women (14% versus 4%; P=0.003) with poorer LVEF (32 [24-45] versus 37 [30-49]; P=0.015) and more advanced NYHA class (III or IV status 44% versus 19%; P<0.001) associated with renal disease in 41% versus 29% (P=0.047) and thyroid disease in 36% versus 24% (P=0.046). They were 61% not inducible at the end of the procedure, compared with the 79% of noninducibility in the procedures followed by PVS day 6 (P<0.001). The procedures not followed by a PVS day 6 more frequently required hemodynamic support (33% versus 15%; P=0.018; Table 1 ).
Forty-two procedures were performed supported by extracorporeal membrane oxygenation; causes were intraprocedural hemodynamic deterioration leading to cardiogenic shock (n=2), preprocedural incessant VT/ electrical storm leading to cardiogenic shock (n=13), high risk in the preoperative assessment and nontolerated VTs (n=23), and prior ineffective substrate modification in sinus rhythm and nontolerated VTs requiring ablation based on entrainment/activation mapping (n=4).
PVS Day 6
Because of the following reasons, 116 procedures (34%) were not followed by a PVS day 6: in-hospital VT recurrences (n=40, 12%), postprocedural hemodynamic impairment (n=26, 8%), comorbidities (n=17, 5%), nonsustained VT (n=5, 1%), recent ICD implantation (n=8, 2%), complications (n=10, 3%), left ventricular assist device implantation (n=4, 1%), permanent atrial fibrillation (n=3, 1%), and 3 patients refused (1%).
Of 218 studies, 32 were invasive, whereas 186 were performed via the ICD in place. Median VTCL of the VTs induced was 310 ms (270-400 ms). Induction of VT was achieved with 1 extrastimulus in 1 patient (2%), 2 extrastimuli in 18 (29%), and 3 extrastimuli in 43 (69%). Out of 62 VT induced, 27 (44%) were interrupted by ATP, 25 (40%) by DC shock, and 10 (16%) were self-terminating. Median follow-up time was 330 days (179-477 days).
Early Versus Late PVS
Concordant results of the acute postprocedural and late programmed stimulation study were observed in 135 of 201 patients (67%; Table 2 ).
To better analyze the predictive value of the early versus late PVS, we compared the long-term VT recurrence-free survival curves, according to each test (Figure 2) . PPV of PVS end ablation was 43% (24/56) and NPV was 71% (173/245). For PVS at day 6, PPV was 53% (33/62) and NVP 88% (138/156).
Predictive Value of PVS According to LVEF and Ischemic Cause
The PVS study performed at the end of the procedure and the survival free from VT recurrence for the different subgroups are shown in Figure 3 .
The PVS day 6 had the highest NPV in the ischemic subgroup (6/68, NPV 91%) and in patients with LVEF >35% (3/82, NPV 96%), when compared with nonischemic (12/88, NPV 86%) and in patients with LVEF ≤35% (15/74, NPV 77%). Figure 4 illustrates the Kaplan-Meier survival curves from VT recurrence stratified for underlying heart disease and LVEF and correlated with the inducibility of VT at day 6 (P<0.001, respectively).
VT Morphology
In 26% of patients (46/174), VT was noninducible at PVS end ablation, but it became reinducible at day 6; this was associated with a higher VT recurrence rate (27/46, 59%), even if 48% of patients were on antiarrhythmic drug (AAD). On the other hand, VT recurrence rate was of 9% (11/128) when both acute and late PVS were negative (29% on AAD therapy), log-rank P<0.001, Figure 5 .
Half of the VTs (23/46) induced at day 6 had been recorded during the index ablation procedure and 16 of 23 were terminated during RF, the remaining 23 were previously nondocumented (median VTCL of 290 ms [260-360 ms]).
Inducible Patients at Day 6
Among 62 patients inducible at day 6, 33 (53%) recurred during follow-up. The VTCL of the clinical recurrence was available in 23 patients, and it was comparable to the induced VTCL in 11 of 23.
Forty-three patients (69%) were discharged on β-blockers and 31 (50%) on AAD after inducibility at day 6 (17 sotalol and 14 amiodarone). Patients discharged with AAD drugs had significantly lower LVEF compared with those on β-blocker (31 [27-39] versus 42 [35-54]; P=0.002). Treatment with AAD was associated with a higher VT recurrence rate (68% versus 39%; P=0.022).
There was no significant difference of VT recurrence rate between patients induced with 1 (100%), 2 (39%), or 3 extrastimuli (46%), P=0.512. However, Survival free from a redo procedure was significantly lower in patients inducible at PVS day 6 (76%) compared with those noninducible (97%, log-rank P<0.001). A total of 24 cases inducible at 6 days underwent a redo procedure, performed epicardially in 7.
Overall, before ablation, there were 32 patients without ICD; 10 of them underwent ICD implantation after the procedure (2 because of an inducible study after ablation and 8 because of an inducible study 6 days later).
Clinical Presentation and Modalities of ICD Treatment of Recurrences
The incidence of syncope was significantly decreased after ablation and ICD programming according to NIPS result (36% versus 3%); similarly, the incidence of electrical storm decreased from 32% to 3%. The number of patients with >5 shocks and the number of patients with any shock were significantly lower in the 6 months after ablation and NIPS-guided programming (from 55% to 2%; P<0.001, and from 87% to 5%; P<0.001, respectively).
Overall, VT recurrence rate was 46 of 185 (25%): VT was treated with shock in 27 of 185 (15%), ATP in 13 of 185 (7%), and in 6 of 185 (3%) it terminated spontaneously or by AAD.
Treatment modalities of VT recurrences according to NIPS results were analyzed to further investigate the contribution of ablation and NIPS-guided ICD programming to patients' outcome ( Table 3 Survival free from appropriate ICD shocks according to NIPS results was 92% if noninducibility was achieved at NIPS, 79% when a nondocumented VT was induced, and 57% when a documented VT was induced (logrank P<0.001; Figure 6 ).
There were no inappropriate shocks. There were 8 syncopal episodes in 6 patients (3%): in 3 patients (5 VT episodes), syncope was because of fast VT terminated by an ICD shock; in 1 patient, it was related to an episode of atrial fibrillation with high ventricular rate; in 1, no arrhythmia cause of syncope was recorded; and in 1 patient, syncope was because of a VT with a cycle length longer than the programmed VT therapy (this patient with low LVEF had prior syncope, and because of an inducible NIPS, he was discharged on amiodarone).
DISCUSSION
This study confirms the superiority of the late assessment, provided by NIPS or by an invasive test, to define the risk of arrhythmia recurrence after ablation when compared with the standard assessment performed immediately after the procedure. Value and limitations of programmed stimulation to predict long-term arrhythmia recurrences have been discussed in single-and multicenter studies. 1, 6, 11 Yokokawa et al 4 confirmed the relation between VT noninducibility in ischemic patient and mortality during longterm FU. Other studies, however, have challenged the reliability of PVS after ablation, as the relation of acute results to long-term outcome is not uniform.
11
Our data show a trend for increased susceptibility to arrhythmia as the time elapses after ablation; 26% of patients not inducible after ablation were inducible 4 to 6 days after, whereas the reversal pattern was observed only seldomly. This divergence goes into an opposite direction from what might be expected, as the stimulation protocol at the end of the procedure includes up to 4 extras up to refractoriness at multiple stimulation sites, whereas the NIPS allows only a maximum of 3 extras from only the right ventricular apex. Longitudinal evaluations with repeated inducibility tests increase the chances of inducing VT because of further factors that may explain the observed test divergence: differences in autonomic tone and degree of sedation with anesthesia, as well as electrophysiological recovery of ablated tissue.
Prognostic Relevance of NIPS
Frankel et al 7 have previously demonstrated that patients with inducible clinical VT at NIPS had markedly decreased 1-year VT-free survival, compared with those in whom no VT was inducible (<30% versus >80%; P=0.001). Similar results were observed in this study; however, compared with that cohort, our population is more commonly represented by patients who were noninducible at the end of the ablation procedure (174 versus 79 patients). A novel finding from our data was the prognostic value of divergent findings obtained at the late study: among patients noninducible after ablation, those who became reinducible shortly thereafter experienced a substantially higher recurrence rate than those who remained noninducible (59% versus 9%).
The finding of late reinduction of the same VT targeted and terminated in the index procedure (16/46) suggests a low sensitivity of the endpoints commonly used to define acute success (termination during radiofrequency delivery of the ongoing VT and noninducibility).
The predictive value of PVS is thought to be lower among patients with poor LVEF, as high recurrence rate has been described independently on the acute outcome. 11 In our experience, even if half of the population is ischemic and this might influence the overall results, the PVS performed a few days after ablation retained prognostic accuracy regardless of cause (ischemic versus non ischemic) and proved valuable also in the group of patients with LVEF <35%.
What to Do After a Positive NIPS Study
Because of the possibility of identifying inducible VTs missed during the acute assessment, new possibilities of further treatment options might be considered. Early redo may be reasonable whenever the doubt of incomplete ablation is consistent. Possible scenarios might include the induction of a VT suggestive of epicardial origin at NIPS after endocardial-only procedures or of untolerated arrhythmias missed at the index procedure; in these cases, a repeat ablation completing an endoepicardial mapping or performing extracorporeal mem- brane oxygenation-supported activation mapping of residual unstable inducible VTs might allow the achievement of a second negative NIPS. 12 Induction of previously nondocumented VT morphologies is also associated to higher recurrence rate. Whereas among ischemic patients, the inducibility of rapid ventricular arrhythmias (cycle length <230 ms) might be nonspecific, Frankel et al 7 found an association between persistent inducible VT with a cycle length >300 ms and VT recurrence during follow-up. 13 No prospective data have provided evidence on the prognostic impact of residual inducible VTs rates with respect to any possible further treatment. Early recurrences are associated with higher mortality; thus, they confer negative prognosis and poses for correction options. 14 Uniform lack of efficacy of the drug treatment undertaken in these cases and multiple side effects seems to support the choice to repeat catheter ablation, rather than escalating AAD treatment, as suggested by the data provided in the VANISH study. 15 In addition to the prognostic significance of VT inducibility, the information provided by the cycle length of the induced arrhythmia was used to guide the ICD programming strategy. In this study, we followed a systematic approach of delayed therapy and programming of ATP tailored to the VTCL induced at NIPS. Our follow-up data confirm the favorable change of the modalities of terminate the recurring VT, reflected by an increased percentage of self-terminating or ATP treated episodes and a concomitant decrease in the use of shock to terminate the VT (−28%, 27 patients over 46 VT recurrences, 59% shocks versus 87% before ablation; P<0.001).
What to Do After a Negative NIPS Study
The low rate of VT recurrence (12%) or ICD shocks (8%) after a noninducible study at NIPS is comparable to that observed in ICD implanted for primary prevention. 16 Several subsets of noninducibility at NIPS imply positive long-term outcome: the absence of inducibility at the end of the procedure and subsequent negative NIPS, noninducible NIPS in case of LVEF >35%, or in case of postinfarction VT, those subgroups may be candidates to primary prevention ICD programming settings with significant benefits. 5, 9 In the present study, high rate ICD therapies cutoff criteria were used, after the MADIT-RIT findings that high rate and delayed arrhythmia detection may favorably affect the prognosis of patients by reducing appropriate and inappropriate therapies. 9 In the ADVANCE III secondary prevention population substudy, a long detection window ICD setting in secondary prevention populations was assigned; the study proved the safety of programming therapies over 188 beats per minute with a significant reduction of the overall therapies and appropriate shocks. 10 Our NIPS study population (median age, 67; LVEF, 37%; syncope, 35%) had similar characteristics to the ADVANCE III substudy (median age, 65; LVEF, 39%; syncope, 52%). The absence of inappropriate shocks and of syncopal episodes with associated injury supports the strategy.
Limitations
Because of several reasons, NIPS was not performed in the entire population limiting its applicability to a selected cohort of patients after VT ablation. The results of the study cannot be entirely extrapolated to patients with advanced functional class or hemodynamic deterioration as PVS at day 6 was performed in only half of them. ICD programming was empirical and not compared with a standard ICD programming. Several ICD manufacturers were used in this study leading to a heterogeneous ICD programming.
Conclusions
NIPS can be considered in the following days after VT ablation to further define the risk of recurrence. A quarter of patients being noninducible at the end of the ablation session have inducible VT just a few days after *Referred to the 6 months before and after ablation. †Referred to the month before and after ablation.
the procedure, with more than half of them recurring at 1-year FU. In case of an inducible NIPS study, the AAD therapy fails to prevent VT recurrence; redo ablation should be an option in selected patients. The programming strategy of high and delayed therapy in noninducible patients at NIPS may be an appropriate option, in view of the high NPV for VT recurrence in this setting.
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